BNC210

Bionomics’ PTSD Candidate Clears Phase IIb Study, Stock Jumps 415%
BioSpace
Fri, 09/29/23 - 10:12 am
Bionomics
PTSD
BNC210
clinical trials
Bionomics' lead asset fails to reduce public speaking anxiety in phase 2 trials
Fierce Biotech
Mon, 12/19/22 - 11:10 am
Bionomics
BNC210
clinical trials
anxiety
public speaking anxiety